查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1590837

青光眼治疗市场：依适应症、类型、销售管道- 2025-2030 年全球预测

Glaucoma Treatment Market by Indication (Angle Closure Glaucoma, Congenital Glaucoma, Open Angle Glaucoma), Type (Alpha Agonist, Beta Blockers, Carbonic Anhydrase Inhibitors), Sales Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年青光眼治疗市场价值为67.3亿美元，预计到2024年将达到73.1亿美元，复合年增长率为8.94%，到2030年将达到122.7亿美元。

青光眼治疗市场对于控制不可逆性失明的主要原因非常重要，包括主要旨在降低眼压和保留视神经功能的各种治疗方法和设备。随着青光眼盛行率的不断上升和世界人口的老化，对有效治疗解决方案的需求不断扩大。市场应用范围涵盖药物治疗（琴酒类似物、 β阻断剂、α-促效剂、碳酸酐酶抑制剂）、雷射治疗、手术介入（小梁切除术、引流植入植入），最终使用者主要包括眼科诊所、医院、研究机构。市场成长的推动因素包括给药系统技术创新的进步、早期诊断意识的提高以及人工智慧的引入以实现更好的疾病管理。然而，高昂的治疗成本和潜在的副作用带来了挑战，需要提高患者对治疗方法的依从性。

主要市场统计
基准年[2023] 67.3亿美元
预测年份 [2024] 73.1亿美元
预测年份 [2030] 122.7亿美元
复合年增长率（%） 8.94%

新型疗法和个人化医疗方法的开发存在着巨大的商机，这与业界向精准医疗的转变一致。公司可以探索与生物技术领域的合作伙伴关係，并投资于缓释性药物配方和微创设备的临床试验。也就是说，监管障碍和冗长的核准流程可能会限制市场动态，凸显了简化核准工作流程的必要性。非侵入性诊断和治疗监测工具的创新具有巨大的成长潜力。此外，透过扩大医疗基础设施进入新兴市场可能是一项盈利的投资。儘管有这些机会，但智慧财产权问题和发展中地区准入有限等挑战仍然存在，需要进行策略调整。了解市场竞争和技术进步的步伐非常重要。因此，企业必须培育强有力的研发倡议，并考虑与学术机构合作进行尖端研究创新，以便在这个不断变化的环境中保持领先地位。这种多方面的方法不仅会加强我们的市场地位，还会提高治疗效率和患者的治疗效果。

市场动态：揭示快速发展的青光眼治疗市场的关键市场洞察

供需的动态交互作用正在改变青光眼治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 随着青光眼发生率的增加，老年人口也增加
    • 政府和製药界不断倡议提高对青光眼的认识
    • 人口中智慧型设备的使用和萤幕时间可能会增加
  • 市场限制因素
    • 欠低度开发国家缺乏早期诊断
  • 市场机会
    • 眼药水技术不断进步
    • 活性化製药和生技公司的研发活动（青光眼治疗）
  • 市场挑战
    • 对药品召回的担忧

波特五力：驾驭青光眼治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解青光眼治疗市场的外在影响

外部宏观环境因素在塑造青光眼治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解青光眼治疗市场的竞争状况

青光眼治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵青光眼治疗市场供应商的绩效评估

FPNV定位矩阵是评估青光眼治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製青光眼治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对青光眼治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年人口增加，青光眼发生率上升
      • 政府和製药组织加大力度提高对青光眼的认识
      • 智慧型装置的使用和萤幕时间可能会增加
    • 抑制因素
      • 开发中国家缺乏早期诊断
    • 机会
      • 眼药水的创新仍在持续
      • 製药和医疗产业的研发活动增加

青光眼治疗生技公司

    • 任务
      • 对药品召回的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章青光眼治疗市场：依适应症分类

  • 隅角闭锁性青光眼
  • 先天性青光眼
  • 开放性青光眼
  • 续发性青光眼

第七章青光眼治疗市场：依类型

  • α促效剂
  • β受体阻断剂
  • 碳酸酐酶抑制剂
  • 胆碱能的
  • 伴随药物
  • 前列腺素琴酒

第八章青光眼治疗市场：依销售管道

  • 医院药房
  • 网上销售
  • 零售药房

第九章美洲青光眼治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太青光眼治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲青光眼治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Accutome, Inc.
  • Akorn Operating Company LLC
  • Alcon Vision LLC
  • Amorphex Therapeutics LLC
  • ASICO LLC
  • Bausch+Lomb Corporation
  • Bayer AG
  • Carl Zeiss Meditec AG
  • Fera Pharmaceuticals, LLC
  • Glaukos Corporation
  • Inotek Pharmaceuticals
  • Lumenis Be Ltd.
  • Merck & Co, Inc.
  • Mobius Therapeutics, LLC
  • NIDEK CO., LTD.
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Perrigo Company PLC
  • Pfizer, Inc.
  • Quantel Medical
  • Santen Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Topcon Corporation
Product Code: MRR-430D3EB72947

The Glaucoma Treatment Market was valued at USD 6.73 billion in 2023, expected to reach USD 7.31 billion in 2024, and is projected to grow at a CAGR of 8.94%, to USD 12.27 billion by 2030.

The glaucoma treatment market, crucial for managing a leading cause of irreversible blindness, predominantly encompasses various therapies and devices aimed at reducing intraocular pressure and preserving optic nerve function. With the rising prevalence of glaucoma and an aging global population, the necessity for effective treatment solutions is expanding. The market's application scope spans medication (prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors), laser therapy, and surgical interventions (trabeculectomy and drainage implants), while end-users primarily include ophthalmology clinics, hospitals, and research institutes. Market growth is fueled by advancing innovations in drug delivery systems, increased awareness of early diagnosis, and the incorporation of artificial intelligence for better disease management. However, high treatment costs and potential side effects pose challenges, alongside the need for improved patient adherence to treatment regimens.

KEY MARKET STATISTICS
Base Year [2023] USD 6.73 billion
Estimated Year [2024] USD 7.31 billion
Forecast Year [2030] USD 12.27 billion
CAGR (%) 8.94%

There are significant opportunities in the development of novel therapeutic agents and personalized medicine approaches, which align with the industry's shift towards precision treatment. Companies can explore partnerships within the biotech sector and invest in clinical trials focusing on sustained-release drug formulations and minimally invasive devices. Nevertheless, regulatory hurdles and lengthy approval processes can constrain market dynamics, emphasizing the need for streamlined approval workflows. Innovating within non-invasive diagnosis and treatment monitoring tools presents substantial growth potential. Further, tapping into emerging markets with expanding healthcare infrastructure offers profitable ventures. Despite these opportunities, persistent challenges such as intellectual property issues and limited accessibility in developing regions require strategic adaptation. Comprehending the competitive nature of the market and the pace of technological advancements is critical. Consequently, businesses must foster robust R&D initiatives to stay ahead in this constantly evolving landscape and consider collaborations with academic institutions for cutting-edge research innovations. This multi-faceted approach not only fortifies market position but also enhances treatment efficiency and patient outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glaucoma Treatment Market

The Glaucoma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing geriatric population coupled with rising incidences of glaucoma
    • Growing government and pharmaceutical organizations initiatives to increase awareness on glaucoma
    • Potential rise in the use of smart gadgets and screen time among the population
  • Market Restraints
    • Lack of early diagnosis in underdeveloped economies
  • Market Opportunities
    • Ongoing technological advancement with eye drops
    • Increasing research and development activities from pharmaceutical and biotechnological companies for glaucoma treatment
  • Market Challenges
    • Concerns associated with drug recalls

Porter's Five Forces: A Strategic Tool for Navigating the Glaucoma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glaucoma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glaucoma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glaucoma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glaucoma Treatment Market

A detailed market share analysis in the Glaucoma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glaucoma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glaucoma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glaucoma Treatment Market

A strategic analysis of the Glaucoma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glaucoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Accutome, Inc., Akorn Operating Company LLC, Alcon Vision LLC, Amorphex Therapeutics LLC, ASICO LLC, Bausch + Lomb Corporation, Bayer AG, Carl Zeiss Meditec AG, Fera Pharmaceuticals, LLC, Glaukos Corporation, Inotek Pharmaceuticals, Lumenis Be Ltd., Merck & Co, Inc., Mobius Therapeutics, LLC, NIDEK CO., LTD., Novartis AG, Ocular Therapeutix, Inc., Perrigo Company PLC, Pfizer, Inc., Quantel Medical, Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and Topcon Corporation.

Market Segmentation & Coverage

This research report categorizes the Glaucoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Angle Closure Glaucoma, Congenital Glaucoma, Open Angle Glaucoma, and Secondary Glaucoma.
  • Based on Type, market is studied across Alpha Agonist, Beta Blockers, Carbonic Anhydrase Inhibitors, Cholinergic, Combined Medications, and Prostaglandin Analogs.
  • Based on Sales Channel, market is studied across Hospital Pharmacies, Online Sales, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing geriatric population coupled with rising incidences of glaucoma
      • 5.1.1.2. Growing government and pharmaceutical organizations initiatives to increase awareness on glaucoma
      • 5.1.1.3. Potential rise in the use of smart gadgets and screen time among the population
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of early diagnosis in underdeveloped economies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing technological advancement with eye drops
      • 5.1.3.2. Increasing research and development activities from pharmaceutical and

biotechnological companies for glaucoma treatment

    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with drug recalls
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Glaucoma Treatment Market, by Indication

  • 6.1. Introduction
  • 6.2. Angle Closure Glaucoma
  • 6.3. Congenital Glaucoma
  • 6.4. Open Angle Glaucoma
  • 6.5. Secondary Glaucoma

7. Glaucoma Treatment Market, by Type

  • 7.1. Introduction
  • 7.2. Alpha Agonist
  • 7.3. Beta Blockers
  • 7.4. Carbonic Anhydrase Inhibitors
  • 7.5. Cholinergic
  • 7.6. Combined Medications
  • 7.7. Prostaglandin Analogs

8. Glaucoma Treatment Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Sales
  • 8.4. Retail Pharmacies

9. Americas Glaucoma Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Glaucoma Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Glaucoma Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Accutome, Inc.
  • 3. Akorn Operating Company LLC
  • 4. Alcon Vision LLC
  • 5. Amorphex Therapeutics LLC
  • 6. ASICO LLC
  • 7. Bausch + Lomb Corporation
  • 8. Bayer AG
  • 9. Carl Zeiss Meditec AG
  • 10. Fera Pharmaceuticals, LLC
  • 11. Glaukos Corporation
  • 12. Inotek Pharmaceuticals
  • 13. Lumenis Be Ltd.
  • 14. Merck & Co, Inc.
  • 15. Mobius Therapeutics, LLC
  • 16. NIDEK CO., LTD.
  • 17. Novartis AG
  • 18. Ocular Therapeutix, Inc.
  • 19. Perrigo Company PLC
  • 20. Pfizer, Inc.
  • 21. Quantel Medical
  • 22. Santen Pharmaceutical Co., Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Topcon Corporation

LIST OF FIGURES

  • FIGURE 1. GLAUCOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLAUCOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLAUCOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GLAUCOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GLAUCOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLAUCOMA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ANGLE CLOSURE GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CONGENITAL GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY OPEN ANGLE GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SECONDARY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ALPHA AGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COMBINED MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. GLAUCOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. GLAUCOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023